AAAAAA

   
Results: 1-8 |
Results: 8
Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim
Authors: Weaver, CH Schulman, KA Buckner, CD
Citation: Ch. Weaver et al., Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim, BONE MAR TR, 27, 2001, pp. S23-S29
Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer
Authors: Mani, S Hochster, H Beck, T Chevlen, EM O'Rourke, MA Weaver, CH Bell, WN White, R McGuirt, C Levin, J Hohneker, J Schilsky, RL Lokich, J
Citation: S. Mani et al., Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer, J CL ONCOL, 18(15), 2000, pp. 2894-2901
Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells
Authors: Weaver, CH Schulman, KA Wilson-Relyea, B Birch, R West, W Buckner, CD
Citation: Ch. Weaver et al., Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells, J CL ONCOL, 18(1), 2000, pp. 43-53
Effect of CD34(+) cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support
Authors: Schulman, KA Birch, R Zhen, B Pania, N Weaver, CH
Citation: Ka. Schulman et al., Effect of CD34(+) cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support, J CL ONCOL, 17(4), 1999, pp. 1227-1233
Adjuvant dose-intense chemotherapy with peripheral blood stem cell supportin stage II-III breast cancer with five to nine involved axillary lymph nodes
Authors: Schwartzberg, LS Birch, R Tauer, KW Leff, R Greco, FA Hainsworth, J Raefsky, E McAneny, B Weaver, Z West, J Buckner, CD Weaver, CH
Citation: Ls. Schwartzberg et al., Adjuvant dose-intense chemotherapy with peripheral blood stem cell supportin stage II-III breast cancer with five to nine involved axillary lymph nodes, AM J CL ONC, 22(2), 1999, pp. 136-142
Single-agent paclitaxel in patients with metastatic breast cancer receiving high-dose chemotherapy with peripheral blood stem cell support
Authors: Schwartzberg, LS Weaver, CH Birch, R Giudice, R Sobong, E Schnell, F Kalman, L Buckner, CD
Citation: Ls. Schwartzberg et al., Single-agent paclitaxel in patients with metastatic breast cancer receiving high-dose chemotherapy with peripheral blood stem cell support, AM J CL ONC, 22(2), 1999, pp. 162-167
High-dose chemotherapy with peripheral blood stem cell support for stage IIIB inflammatory carcinoma of the breast
Authors: Schwartzberg, LS Weaver, CH Lewkow, L McAneny, B Zhen, B Birch, R West, WH Tauer, KW Buckner, CD
Citation: Ls. Schwartzberg et al., High-dose chemotherapy with peripheral blood stem cell support for stage IIIB inflammatory carcinoma of the breast, BONE MAR TR, 24(9), 1999, pp. 981-987
Mobilization of peripheral blood stem cells with docetaxel and cyclophosphamide (CY) in patients with metastatic breast cancer: a randomized trial of3 vs 4 g/m(2) of CY
Authors: Weaver, CH Schwartzberg, LS Zhen, B Franco, C Moore, M Smith, R White, L Van Amburg, A Hazelton, B Buckner, CD
Citation: Ch. Weaver et al., Mobilization of peripheral blood stem cells with docetaxel and cyclophosphamide (CY) in patients with metastatic breast cancer: a randomized trial of3 vs 4 g/m(2) of CY, BONE MAR TR, 23(5), 1999, pp. 421-425
Risultati: 1-8 |